When Al Mann first said he was going to develop an inhaled insulin, many thought he was beating a dead horse after the collective experiences with Exubera. They forgot that Al had already built the most successful pump company of all times, and that he did not like to fail. …

Diabetes is a huge and growing problem, and the costs to society are high and escalating. More was spent in 2013 in North America and the Caribbean than in any other region. The Top 5 countries for prevalence in North America and the Caribbean are: Belize, Guyana, Curacao, Martinique, and …

  With this week’s Homerun Slides, we have a short special presentation for you on the new inhaled insulin, Afrezza, that goes with our exclusive interview by our publisher, Steve Freed, with the founder and CEO of Mannkind Corp, Al Mann….

This week, we are taking a break from our Clinical Text presentations, to bring you this exclusive interview with Al Mann, the legendary founder of Mannkind Corp, and the person primarily responsible for backing the development of the inhaled insulin product, Afrezza, soon to be on the market. Steve Freed: …

As new medications for diabetes come to market there is always a question as to how well they will work when added to other medications. This month, we have a slide presentation from the ADA, outlining the rationale for mating DPP-4 inhibitors with SGLT-2 inhibitors. 

As the diabetes epidemic continues to grow, practitioners are increasingly searching for medication solutions that can help patients to better manage their diabetes. This month, we have a recent slides series from the ADA showing the positive effects of adding-on SGLT-2 inhibitors to the medication regimen of patients on DPP-4’s …